Gsa Capital Partners LLP Cidara Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$0.64 - $0.92 $53,657 - $77,132	-83,840 Reduced 15.51%	456,606 $420,000
Q4 2023 Feb 16, 2024	BUY	$0.68 - $0.97 $274,360 - $391,367	403,472 Added 294.56%	540,446 $426,000
Q3 2023 Nov 15, 2023	BUY	$0.77 - $1.16 $105,469 - $158,889	136,974 New	136,974 $128,000
Q2 2021 Aug 05, 2021	SELL	$1.87 - $2.7 $334,228 - $482,576	-178,732 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$2.06 - $3.01 $1,612 - $2,356	-783 Reduced 0.44%	178,732 $475,000
Q4 2020 Feb 03, 2021	BUY	$1.99 - $3.25 $305,815 - $499,447	153,676 Added 594.74%	179,515 $359,000
Q3 2020 Nov 06, 2020	BUY	$2.85 - $4.1 $73,641 - $105,939	25,839 New	25,839 $74,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.63B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.